Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Lysergamide

LSD-25

C20H25N3O CAS 50-37-3 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bevorzugter Name
LSD-25
IUPAC-Name
(6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS-Nummer der Stammverbindung (Referenz)
50-37-3
Summenformel
C20H25N3O
Molekulargewicht
323.4 g/mol
InChIKey
VAYOSLLFUXYJDT-RDTXWAMCSA-N
PubChem
CID 5761
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
Lysergide Lysergic acid diethylamide LSD LSD25

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

LSD-25

Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist) Lysergamide
Geprüfte PubChem- & CAS-Identität C20H25N3O · CAS 50-37-3 · CID 5761
Kalibrierte Lieferform Gelöste Flüssigkeitslösung (µg-kalibriert)
≥98 % analytische Reinheit geprüft 323.4 g/mol
WHO-, PubMed- & PubChem-Quellen 2 cited records

Rezeptor-Telemetrie & Wirkmechanismus

5-HT₂ₐ Perceptual & Visual Signaling Partial Agonist
5-HT₁ₐ / 5-HT₂c Serotonergic Modulation Active
D₂ / Adrenergic Dopaminergic / Somatic Tone Moderate

Prototypical ergoline partial agonist at 5-HT2A (Ki ~2.9 nM) with prolonged receptor 'lid' residence time (Wacker et al., Cell 2017) plus 5-HT1A and D2 signaling.

Biotransformation & Active Metabolites

Hepatic CYP2D6/3A4/1A2 oxidation to inactive 2-oxo-3-hydroxy-LSD (plasma T1/2 ~3.6 h).

Zeitliche Pharmakokinetik

Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist) — Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x).

  1. Onset 30–60 min
  2. Peak Window 2–4 h
  3. Total Window 8–12 h
  4. Residual / Half-Life 4–8 h residual wakefulness

Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x).

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
10–20 ug
Cognitive & Sensory

Subtle threshold receptor activity (Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
25–75 ug
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
75–150 ug
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
150–300 ug
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
300+ ug
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

Lithium salts

Strongly documented to provoke acute tonic-clonic seizures, fugue states, and severe psychotic episodes with lysergamides.

Tramadol

Lowers seizure threshold alongside 5-HT2A excitation.

Hohes Risiko — Vermeiden

Cannabis & Strong Stimulants (Cathinones, Amphetamines, Cocaine)

Exponentially amplifies thought loops, tachycardia, anxiety, and acute paranoia.

Vorsicht / Abschwächung

SSRIs / SNRIs & Benzodiazepines

Chronic SSRIs and acute benzodiazepines markedly attenuate 5-HT2A perceptual effects.

Isomeren- & Strukturvergleich

Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x).

Stabilität & Lagerung

Form: Clear, colorless calibrated liquid solution for microgram (µg) volumetric measurement. · Supplied pre-dissolved in analytical carrier; sensitive to chlorine/tap water.

Highly sensitive to UV light, heat, and chlorine; store airtight in amber glass under cold/refrigerated conditions.

Cross-Tolerance & Dependence Profile

Immediate rapid 5-HT2A receptor downregulation within hours, cross-tolerant with all tryptamines and phenethylamines; baseline sensitivity typically resets over 10–14 days. Non-addictive physiologically.

Analytische & toxikologische Monographie

LSD-25 ((6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; CAS 50-37-3, PubChem CID 5761) is a lysergamide reference compound (C20H25N3O, 323.4 g/mol) classified pharmacologically as a Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist). Prototypical ergoline partial agonist at 5-HT2A (Ki ~2.9 nM) with prolonged receptor 'lid' residence time (Wacker et al., Cell 2017) plus 5-HT1A and D2 signaling. Hepatic CYP2D6/3A4/1A2 oxidation to inactive 2-oxo-3-hydroxy-LSD (plasma T1/2 ~3.6 h). In published observational and toxicological literature, threshold response is noted at 10–20 ug, light range at 25–75 ug, common reference range at 75–150 ug, strong intensity at 150–300 ug, and heavy/adverse territory at 300+ ug, with an onset of 30–60 min, peak window of 2–4 h, and total duration of 8–12 h (4–8 h residual wakefulness). Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x). Critical contraindications include Lithium salts, Tramadol.

Chemische Struktur und Molekülprofil

LSD-25 ((6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide) ist eine Referenzverbindung aus der Stoffklasse Lysergamide mit der Summenformel C20H25N3O und einer molaren Masse von 323.4 g/mol. Die Stammverbindung wird unter der CAS-Nummer 50-37-3 sowie in der NCBI-PubChem-Datenbank unter CID 5761 geführt (Standard-InChIKey: VAYOSLLFUXYJDT-RDTXWAMCSA-N).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört LSD-25 zur chemischen Klasse Lysergamides. Toxikologische Hinweise (PsychonautWiki): sehr geringe akute Toxizität im Verhältnis zur Stoffmenge. Abhängigkeitspotenzial (PsychonautWiki): kein dokumentiertes physisches Abhängigkeitspotenzial. Dokumentierte Kreuztoleranz: psychedelics. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen

Dokumentierte Wechselwirkungen und Kontraindikationen

Hohes Risiko / Gefährliche Kombinationen

Unsichere Kombinationen (erhöhtes Risiko)

Ungeklärte Wechselwirkungen (Vorsicht geboten)